City of Hope Medical Center: Carcinoma, Renal Cell trials
The registry lists 22 Carcinoma, Renal Cell studies with City of Hope Medical Center as lead sponsor. 6 are open to participants now and 2 have results posted.
Phase 1 7Phase 2 7No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyNot yet recruitingNCT07578025Phase 2
- Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell CancerRecruitingNCT07226544Phase 2
- Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerRecruitingNCT07128680Phase 1
- Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After SurgeryRecruitingNCT07037004Phase 2
- Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell CarcinomaRecruitingNCT05830058Phase 2
- Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary CancersRecruitingNCT05519878Not applicable
- Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase InhibitorCompletedNCT02944617Not applicableResults posted
- Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney CancerCompletedNCT01157091Phase 2Results posted
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnNCT07218692Phase 2
- STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
- Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaSuspendedNCT06049576Phase 1
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingNCT05122546Phase 1
- Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell CarcinomaWithdrawnNCT04961320Not applicable
- App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell CancerActive, not recruitingNCT04788095Not applicable
- iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell CarcinomaWithdrawnNCT04688333
- Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesCompletedNCT04501913
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCompletedNCT03829111Phase 1
- Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
- Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung CancersCompletedNCT01846520Not applicable
- Fluorescence Imaging in Finding Tumors in Patients With Kidney TumorsCompletedNCT01281488Phase 1
- Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney CancerCompletedNCT00806650
- SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00006384Phase 2